{"id":"W4396515165","doi":"10.1182/bloodadvances.2024012646","title":"Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Filgrastim; Term (time); Peripheral blood; Stem cell; Peripheral Blood Stem Cells; Medicine; Immunology; Internal medicine; Granulocyte colony-stimulating factor; Hematopoietic stem cell transplantation; Biology; Transplantation; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001008283,0.0002522233,0.0005140972,0.0001225217,0.00003752614,0.0000238212,0.00009650896,0.0000940188,0.000227878],"category_scores_gemma":[0.000005473941,0.0001731626,0.0001247998,0.0003196956,0.0001094345,0.0001677031,0.00001129501,0.0001814202,0.00002110961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000150732,"about_ca_system_score_gemma":0.0001079665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001245472,"about_ca_topic_score_gemma":0.00002727319,"domain_scores_codex":[0.9985341,0.00003853321,0.0004263655,0.000377756,0.0003616709,0.0002615676],"domain_scores_gemma":[0.9992434,0.0002078927,0.00009268754,0.0002654628,0.00007174469,0.0001187764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003940824,0.0009073517,0.9520642,0.005959123,0.000973178,0.001143231,0.001946511,0.0001604177,0.03330449,0.0001597402,0.00001229002,0.00297537],"study_design_scores_gemma":[0.01926681,0.003341315,0.3209535,0.005392004,0.007702001,0.001482594,0.001105772,0.0003246319,0.638903,0.00008394045,0.0004895225,0.0009549105],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98753,0.008335115,0.0006719636,0.00008949977,0.0002095865,0.0005728811,0.00003224483,0.0002106681,0.002348021],"genre_scores_gemma":[0.9945187,0.0007671311,0.00213352,0.00003249844,0.00003796536,0.00004656878,0.00004639083,0.00004803829,0.002369173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6311107,"threshold_uncertainty_score":0.7061365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01205772023276805,"score_gpt":0.2696585224523246,"score_spread":0.2576008022195565,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}